Azenta (AZTA) Q3 2023: Automated Store Revenue Jumps 15%, Underscoring Workflow Automation Tailwind
Azenta’s Q3 results highlight robust demand for automated sample management systems and a strategic pivot toward integrated, high-value life sciences solutions. Despite persistent consumables headwinds, targeted cost actions and segment realignment are driving margin recovery and operational leverage. Management’s focus on automation, cross-segment synergies, and disciplined capital deployment sets the stage for continued outperformance in a challenging market.
Summary
- Automation-Driven Growth: Automated store systems delivered record revenue, signaling secular workflow automation demand.
- Consumables Drag Persists: Channel inventory overhang continues to weigh on legacy consumables, but instruments strength offers a leading indicator for recovery.
- Strategic Realignment: Segment integration and cost reductions expand operational leverage and position Azenta for sustainable growth.
Business Overview
Azenta provides sample management and multiomics services to life sciences, biopharma, and research customers. The company operates through two primary segments: Services (genomics, gene synthesis, sample repository solutions) and Products (automated storage systems, consumables, and instruments). Revenue is generated from storage, processing, and analysis of biological samples, as well as the sale of automation hardware and consumables. Recent acquisitions, including B Medical, have expanded its cold chain and emerging market footprint.
Performance Analysis
Azenta posted strong top-line growth, with total revenue up 25% year over year and 12% sequentially, propelled by acquisitions and robust organic expansion in automation and repository services. Organic growth, excluding the challenged consumables and instruments (CNI) business, was 8%, demonstrating the resilience and momentum of the core portfolio. Automated store systems revenue surged 15% year over year and 23% sequentially, reflecting a record quarter and substantial backlog conversion.
The Services segment delivered 8% organic growth, with genomics and sample repository solutions both outpacing peers. Genomics growth was led by next-generation sequencing (NGS), up 13% year over year, and gene synthesis, up 9% sequentially. Gross margin improved four points quarter over quarter to 45.6%, aided by cost reduction actions and non-recurring product segment adjustments. However, CNI remained a drag, down 24% year over year and representing 11% of total revenue, as customer inventory destocking persisted.
- Automated Store Outperformance: Record installations and a strong backlog signal sustained demand for workflow automation across biopharma and research customers.
- Services Margin Stability: Gross margin in services improved sequentially, driven by operating leverage and targeted sales investment.
- Consumables Weakness: Channel inventory remains elevated, with limited visibility on normalization, but instrument sales strength suggests future recovery potential.
Azenta’s free cash flow turned positive for the first time as a standalone life sciences company, marking an inflection in operational discipline and capital efficiency.
Executive Commentary
"We're substantially aligned to implement a new reporting structure beginning October 1st, which we expect will significantly improve our operating efficiency while better aligning our offerings to customer needs."
Steve Schwartz, President and Chief Executive Officer
"If you remove [CNI], our organic growth is quite remarkably different than the rest of the market, and this is where Steve had emphasized in his remarks. We really believe that the marketing and sales actions and the value of our portfolio across the other 90% is really standing out in the market, and we couldn't be more pleased with how the market's accepting and taking it."
Lyndon Robertson, Chief Financial Officer
Strategic Positioning
1. Integrated Segment Realignment
Azenta is merging its sample repository solutions and life sciences products businesses to create a unified asset management offering. This move enables seamless cross-selling of automation and repository services, driving higher customer value and stickiness. The new structure is designed to support cross-segment sales and operational efficiency as the company enters fiscal 2024.
2. Automation as a Secular Growth Engine
Automated store systems are now the primary growth lever, with over 60 million samples of automated storage capacity added in the past eight quarters. Management expects large-scale manual freezer farms to be replaced by automated solutions, positioning Azenta as a key enabler of the industry’s shift to higher efficiency and safer sample handling.
3. Disciplined Capital Deployment
Azenta has completed over three-fourths of its $1 billion share repurchase program, retiring 20% of outstanding shares while maintaining a $1 billion cash war chest. Investments in new capacity, product innovation, and M&A remain central to the long-term growth strategy, with B Medical’s geographic reach and cold chain expertise offering synergy upside.
4. Margin Expansion Through Cost Actions
Cost reduction initiatives are showing through in margin improvement, with the first phase completed and a second phase underway. These actions are expected to deliver an additional $15 million in annualized savings by the end of the calendar year, supporting EBITDA leverage as revenue scales.
5. Geographic and Service Diversification
China delivered close to 20% growth in genomics, outpacing expectations and providing a counterweight to broader market caution. The company’s Suzhou facility supports both local and global gene synthesis and sequencing demand, reinforcing Azenta’s international diversification strategy.
Key Considerations
Azenta’s Q3 demonstrated that the company’s strategic bets on automation, integration, and operational discipline are gaining traction, but challenges in legacy consumables and macro-driven CapEx caution remain unresolved.
Key Considerations:
- Automation Adoption Curve: The secular shift from manual to automated sample management is accelerating, with Azenta capturing share through differentiated technology and integrated service models.
- Consumables Channel Overhang: Persistent inventory at customer sites continues to suppress consumables revenue, with management signaling only gradual normalization.
- Operational Leverage: Cost actions and segment realignment are improving profitability, but future gains hinge on execution of the second phase of cost reductions and successful integration of acquisitions.
- End-Market Sensitivity: Biopharma CapEx caution is delaying some cryo automation projects, though automated store backlog remains robust and instrument sales provide a leading indicator for recovery.
- Capital Allocation Discipline: Aggressive buybacks and a strong balance sheet provide flexibility for further investment and M&A, but also raise expectations for sustained returns on capital.
Risks
Azenta faces ongoing risk from protracted consumables destocking, which could extend revenue softness longer than anticipated. Delays in biopharma CapEx and project starts may impact cryo automation and repository growth. Integration of acquisitions and realization of synergy targets present execution risk, while aggressive capital return raises the bar for future cash flow generation. Currency fluctuations and competitive pricing pressure in gene synthesis also warrant continued monitoring.
Forward Outlook
For Q4, Azenta guided to:
- Total revenue of $155 million to $173 million (midpoint up 19% YoY as reported)
- Adjusted EBITDA of $2 million to $9 million (approximately 5% margin at midpoint)
For full-year 2023, management narrowed guidance to:
- Total revenue of $648 million to $665 million (17% to 20% growth YoY)
Management expects continued strength in automated stores and repository solutions, ongoing CNI softness, and a modest FX tailwind. The second phase of cost reductions is on track for completion by year-end, with incremental margin benefit expected in fiscal 2024. Acquisitions, particularly B Medical, will remain a key driver of reported growth and emerging market expansion.
Takeaways
Azenta’s Q3 results confirm that workflow automation and integrated sample management are the company’s primary growth vectors, with cost discipline and capital deployment amplifying returns.
- Automation Tailwind: Record automated store revenue and backlog signal durable secular demand, even as legacy consumables remain under pressure.
- Margin and Structure Inflection: Cost reductions and segment integration are driving improved profitability and operational focus, setting up for further leverage in 2024.
- Recovery Watch: Instrument sales strength could foreshadow a turning point in consumables, while biopharma CapEx caution and project delays remain a watchpoint for repository and cryo automation growth.
Conclusion
Azenta’s Q3 was defined by strong execution in automation, disciplined cost management, and a clear pivot toward integrated, high-value solutions. While legacy consumables remain a drag, the company’s strategic realignment and capital deployment position it for outperformance as industry demand shifts toward automation and efficiency.
Industry Read-Through
Azenta’s results reinforce the accelerating transition from manual to automated sample management across life sciences, with workflow automation emerging as a critical competitive differentiator. The persistent drag from consumables destocking is a cautionary signal for peers exposed to legacy lab supply channels, while the strong performance in automated stores and genomics points to where secular growth is concentrating. Biopharma CapEx caution and project delays, as cited by Azenta and its peers, suggest a near-term headwind for capital equipment providers, but the long-term trajectory remains positive for those positioned in automation and integrated services. Investors should monitor instrument sales as a lead indicator for consumables recovery and broader market normalization.